Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1959 2
1960 1
1968 2
1969 2
1970 1
1971 2
1972 6
1973 3
1974 4
1975 1
1976 16
1977 13
1978 14
1979 16
1980 12
1981 16
1982 25
1983 13
1984 29
1985 28
1986 32
1987 45
1988 35
1989 66
1990 79
1991 97
1992 117
1993 133
1994 154
1995 150
1996 166
1997 186
1998 187
1999 221
2000 228
2001 235
2002 267
2003 302
2004 291
2005 274
2006 250
2007 233
2008 203
2009 188
2010 200
2011 246
2012 199
2013 186
2014 172
2015 175
2016 116
2017 135
2018 153
2019 139
2020 122
2021 142
2022 122
2023 125
2024 116
2025 158
2026 70

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,460 results

Results by year

Filters applied: . Clear all
Page 1
Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, Brandi ML, Cano A, Collins P, Cooper C, Genazzani AR, Hillard T, Kanis JA, Kaufman JM, Lambrinoudaki I, Laslop A, McCloskey E, Palacios S, Prieto-Alhambra D, Reginster JY, Rizzoli R, Rosano G, Trémollieres F, Harvey NC. Rozenberg S, et al. Osteoporos Int. 2020 Dec;31(12):2271-2286. doi: 10.1007/s00198-020-05497-8. Epub 2020 Jul 8. Osteoporos Int. 2020. PMID: 32642851 Free PMC article. Review.
We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal health and prevention of future fractures in recently menopausal women. Despite controversy over associated side effects, which has limited its u …
We provide an evidence base and guidance for the use of menopausal hormone therapy (MHT) for the maintenance of skeletal healt …
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Eastell R, et al. J Clin Endocrinol Metab. 2019 May 1;104(5):1595-1622. doi: 10.1210/jc.2019-00221. J Clin Endocrinol Metab. 2019. PMID: 30907953 Free article.
OBJECTIVE: The objective is to formulate clinical practice guidelines for the pharmacological management of osteoporosis in postmenopausal women. CONCLUSIONS: Evidence from clinical trials and insights from clinical experience with pharmacologic therapies for …
OBJECTIVE: The objective is to formulate clinical practice guidelines for the pharmacological management of osteoporosis in postme …
Hormone therapy for postmenopausal osteoporosis management.
Jiang X, Kagan R. Jiang X, et al. Climacteric. 2022 Feb;25(1):50-55. doi: 10.1080/13697137.2021.1957818. Epub 2021 Aug 17. Climacteric. 2022. PMID: 34402365
Menopausal hormone therapy (MHT) has been used for prevention and treatment of postmenopausal osteoporosis for several decades. ...We conducted a historical review on this subject, primarily focusing on level I evidence from randomized controlled trial …
Menopausal hormone therapy (MHT) has been used for prevention and treatment of postmenopausal osteoporosis for s …
Postmenopausal osteoporosis and hormone replacement therapy.
Gambacciani M, Vacca F. Gambacciani M, et al. Minerva Med. 2004 Dec;95(6):507-20. Minerva Med. 2004. PMID: 15785435 Review. English, Italian.
Postmenopausal osteoporosis is a major public health problem. Estrogen deficiency is a key factor in the pathogenesis of postmenopausal osteoporosis. Among the several types therapeutic intervention in osteoporosis, hormone replacement …
Postmenopausal osteoporosis is a major public health problem. Estrogen deficiency is a key factor in the pathogenesis of po …
Prevention and treatment of postmenopausal osteoporosis.
Tella SH, Gallagher JC. Tella SH, et al. J Steroid Biochem Mol Biol. 2014 Jul;142:155-70. doi: 10.1016/j.jsbmb.2013.09.008. Epub 2013 Oct 29. J Steroid Biochem Mol Biol. 2014. PMID: 24176761 Free PMC article. Review.
This continued until the Women's Health Initiative (WHI) study in 2001 that published data on 6 years of treatment with hormone therapy that showed an increase in heart attacks and breast cancer. Even though the risks were small, 1 per 1500 users annually, patients …
This continued until the Women's Health Initiative (WHI) study in 2001 that published data on 6 years of treatment with hormone th …
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Neer RM, et al. N Engl J Med. 2001 May 10;344(19):1434-41. doi: 10.1056/NEJM200105103441904. N Engl J Med. 2001. PMID: 11346808 Free article. Clinical Trial.
METHODS: We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid hormone (1-34) or placebo, administered subcutaneously by the women daily. ...Both doses increased total-body bone mineral by 2 to 4 more …
METHODS: We randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive 20 or 40 microg of parathyroid h …
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators. Miller PD, et al. JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. JAMA. 2016. PMID: 27533157 Clinical Trial.
IMPORTANCE: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor. ...[table: see text]. CONCLUSIONS AND RELEVANCE: Among postmenopausal women with osteop …
IMPORTANCE: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the p …
Recent Advances in Osteoporosis Therapeutics.
Sølling AS, Langdahl BL, Cosman F. Sølling AS, et al. Annu Rev Med. 2026 Jan;77(1):433-448. doi: 10.1146/annurev-med-050124-040555. Epub 2025 Nov 18. Annu Rev Med. 2026. PMID: 41252575 Free article. Review.
Postmenopausal osteoporosis is a chronic progressive disease related to estrogen deficiency at menopause, aging, and superimposed genetic and environmental factors. ...Recent guidelines have suggested categorical risk stratification and a goal-directed individualize …
Postmenopausal osteoporosis is a chronic progressive disease related to estrogen deficiency at menopause, aging, and superimpo …
Postmenopausal osteoporosis.
Watts NB. Watts NB. Obstet Gynecol Surv. 1999 Aug;54(8):532-8. doi: 10.1097/00006254-199908000-00024. Obstet Gynecol Surv. 1999. PMID: 10434274 Free article. Review.
Low bone density is the most important risk factor for osteoporosis. The National Osteoporosis Foundation recommends bone density testing for all women over 65 and earlier (around the time of menopause) for women who have risk factors or who are considering thera …
Low bone density is the most important risk factor for osteoporosis. The National Osteoporosis Foundation recommends bone dens …
6,460 results